The candidate vaccine known as CoronaVac is one of the few vaccines that have entered the Phase 3 trial for a large-scale study.
Sinovac Biotech Ltd. of China presented a phase 3 human trial of a COVID-19 vaccine candidate on August 11, 2020, involving up to 1,620 patients in Indonesia. Sinovac developed the vaccine with its Indonesian state counterpart, Bio-Farma.
Sinovac also released the main points on August 10 of the Phase 2 study in which he stated that the COVID-19 vaccine candidate gave the impression and had induced detectable immune responses based on antibodies in patients.
The candidate vaccine, known as CoronaVac, is one of the few prospective vaccines that entered the Phase 3 trial to collect large-scale testing for regulatory approval.
The CoronaVac vaccine goes into the testing phase:
CoronaVac has already been the subject of a phase 3 human trial in Brazil and Sinovac also plans to do so in Bangladesh.
Joko Widodo, Indonesia’s president in a test release rite in West Java, said the coronavirus will not calm down until the effective vaccine is administered to the entire population. Let’s hope that in January the government will produce and vaccinate everyone in the country.
Sinovac has tested its vaccine because China is no longer an acceptable site for Phase 3 trials because the number of new infections is low.
In addition to Bio Farma of Indonesia and Sinovac, South Korean company Genexine and Indonesian company Kalbe Farma have also cooperated to produce a separate set of vaccines.
What do the main published points of the phase 2 human trial imply?
In the Phase 2 human trial of Sinovac, which involved 600 patients from China, the fever rate in them was found to be lower than that of other COVID-19 patients.
The mid-term trial or phase 2 human trial sometimes tests a candidate’s protection and ability to provoke an immune reaction in a small number of other people before entering the third phase of the trial.
According to reports, the published study noted that the production procedure for vaccines used in the Phase 2 trial was more optimized than in the Phase 1 trial, which also produced more immunogens and led to greater immune responses.
According to Sinovac’s spokesman, vaccines used in Phase 3 of human trials will be manufactured through the optimized process.
The researchers also noted that the effects of Phase 2 included only antibody-based immunity and added that the candidate had been evaluated for other parts of the immune system.